 Lindsay Brubaker
Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 7 | 2024 | 565 | 1.970 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2024 | 50 | 1.660 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 115 | 1.070 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 801 | 0.690 |
Why?
| | Phthalazines | 1 | 2019 | 45 | 0.630 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 105 | 0.610 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2019 | 77 | 0.600 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 136 | 0.560 |
Why?
| | Piperazines | 1 | 2019 | 350 | 0.540 |
Why?
| | Genital Neoplasms, Female | 2 | 2020 | 90 | 0.320 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2020 | 64 | 0.320 |
Why?
| | Intrauterine Devices | 1 | 2019 | 31 | 0.310 |
Why?
| | Surgical Oncology | 1 | 2019 | 27 | 0.310 |
Why?
| | Cancer Pain | 1 | 2019 | 29 | 0.310 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2129 | 0.300 |
Why?
| | Neoplasms | 1 | 2023 | 2671 | 0.290 |
Why?
| | Pain, Postoperative | 1 | 2019 | 265 | 0.260 |
Why?
| | Pain Management | 1 | 2019 | 352 | 0.250 |
Why?
| | Teratoma | 1 | 2016 | 114 | 0.230 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 77 | 0.220 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 28 | 0.210 |
Why?
| | Struma Ovarii | 1 | 2022 | 7 | 0.200 |
Why?
| | Analgesics, Opioid | 1 | 2019 | 1000 | 0.180 |
Why?
| | Lysine | 1 | 2023 | 294 | 0.170 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 13 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 683 | 0.170 |
Why?
| | Enoxaparin | 1 | 2020 | 63 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 210 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 307 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2016 | 940 | 0.150 |
Why?
| | Thyroid Neoplasms | 1 | 2022 | 343 | 0.150 |
Why?
| | Female | 11 | 2024 | 73304 | 0.140 |
Why?
| | Sarcoma | 1 | 2020 | 188 | 0.140 |
Why?
| | Peptides | 1 | 2023 | 985 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.130 |
Why?
| | Pyrazoles | 1 | 2020 | 423 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 872 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 316 | 0.120 |
Why?
| | Humans | 12 | 2024 | 137585 | 0.120 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 63 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 664 | 0.120 |
Why?
| | Animals | 3 | 2024 | 36940 | 0.110 |
Why?
| | Histones | 1 | 2019 | 636 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1774 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2757 | 0.090 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3412 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2020 | 2654 | 0.070 |
Why?
| | Gynecology | 1 | 2020 | 168 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2019 | 245 | 0.070 |
Why?
| | Preoperative Care | 1 | 2019 | 362 | 0.070 |
Why?
| | Middle Aged | 5 | 2021 | 33479 | 0.060 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2016 | 77 | 0.060 |
Why?
| | Paclitaxel | 1 | 2016 | 230 | 0.060 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 327 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2020 | 7635 | 0.050 |
Why?
| | Incidence | 1 | 2019 | 2804 | 0.050 |
Why?
| | Iodine Radioisotopes | 1 | 2022 | 145 | 0.050 |
Why?
| | Mice | 1 | 2019 | 17787 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 15657 | 0.050 |
Why?
| | Vulvectomy | 1 | 2020 | 2 | 0.040 |
Why?
| | Dermatofibrosarcoma | 1 | 2020 | 9 | 0.040 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2020 | 6 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 2020 | 28 | 0.040 |
Why?
| | Liposarcoma | 1 | 2020 | 27 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 72 | 0.040 |
Why?
| | Radiotherapy | 1 | 2020 | 201 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 227 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2020 | 171 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 352 | 0.040 |
Why?
| | Young Adult | 2 | 2020 | 13209 | 0.040 |
Why?
| | Cohort Studies | 1 | 2019 | 5742 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1325 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2016 | 855 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 889 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1266 | 0.030 |
Why?
| | Aged | 2 | 2020 | 23961 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1972 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2253 | 0.030 |
Why?
| | Adult | 2 | 2020 | 37929 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2016 | 10811 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2892 | 0.020 |
Why?
| | United States | 1 | 2020 | 14841 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 21513 | 0.010 |
Why?
|
|
Brubaker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|